CISS (CISS) Stock Price & Analysis
CISS (CISS) rose 5.66% to USD 2.24 as of June 10, 2026 at 09:03 UTC, according to Nexqual real-time market data.
CISS last closed at USD 2.12; the session ranged USD 2.08–2.31 on volume of 429,488 shares. Market capitalization is $1.21M, with a 52-week range of USD 1.9–831.6 (NCM). Source: Nexqual, June 10, 2026 at 09:03 UTC.
Key Statistics (as of June 10, 2026 at 09:03 UTC)
| Price | USD 2.24 |
|---|---|
| Change | ▲ 5.66% (up) |
| Previous Close | USD 2.12 |
| Open | USD 2.19 |
| Day Range | USD 2.08 – 2.31 |
| 52-Week Range | USD 1.9 – 831.6 |
| Volume | 429,488 shares |
| Market Cap | $1.21M |
| Exchange | NCM |
Technical Analysis (CISS)
Nexqual's technical model rates CISS "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 09:03 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 20.97 (oversold) |
| vs SMA50 | Below (USD 3.87) |
| MACD | -0.54 (negative) |
Analyst Ratings (CISS)
Wall Street analysts rate CISS "None", per Nexqual as of June 10, 2026 at 09:03 UTC.
| Consensus Rating | None |
|---|
Earnings (CISS)
| Next Earnings Date | 2026-08-04 |
|---|
Source: Nexqual, June 10, 2026 at 09:03 UTC.
Financials & Fundamentals (CISS)
| Total Revenue | $37.66M |
|---|---|
| Revenue Growth (YoY) | +33.50% |
| Gross Margin | +67.62% |
| Operating Margin | +45.48% |
| Profit Margin | +15.29% |
| ROE | +6.35% |
| Debt / Equity | 0.01 |
| Current Ratio | 8.51 |
| Total Cash | $27.26M |
| Total Debt | $7,853 |
| Free Cash Flow | $-6.06M |
Source: Nexqual, June 10, 2026 at 09:03 UTC.
Financial Health Score (CISS)
Nexqual rates CISS's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 09:03 UTC.
| Growth | Strong — Revenue +34% YoY (latest Q) |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Strong — $27M cash, no debt |
| Cash Flow | Weak — FCF negative: -$6M, burning cash |
| Efficiency | Mixed — ROE 6%, ROA 3.2% |
Ownership (CISS)
| Insider Ownership | +1.37% |
|---|---|
| Institutional Ownership | +9.16% |
| Shares Outstanding | 541,088 |
| Float | 323,160 |
| Short % of Float | +8.99% |
Source: Nexqual, June 10, 2026 at 09:03 UTC.
Leadership (CISS)
CISS is led by Diamantis Andriotis (age 42), CEO, President & Director, per Nexqual as of June 10, 2026 at 09:03 UTC.
| CEO, President & Director | Diamantis Andriotis (age 42) |
|---|---|
| Chief Financial Officer | Nina Pyndiah (age 62) |
Major Backers & Investors (CISS)
Notable institutional backers of CISS include HRT Financial LP, Stonex Group Inc., according to Nexqual as of June 10, 2026 at 09:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| HRT Financial LP | 2.02% |
| Stonex Group Inc. | 0.28% |
Source: Nexqual, June 10, 2026 at 09:03 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AKAN | Akanda Corp. | USD 13.76 | ▼ 11.96% |
| MGRX | Mangoceuticals, Inc. | USD 0.34 | ▼ 4.48% |
| BDRX | Biodexa Pharmaceuticals plc | USD 3.1 | ▼ 7.74% |
| RENX | RenX Enterprises Corp. | USD 1.7 | ▼ 0.58% |
| IVPR | Inspire Veterinary Partners Inc | USD 0 | ▼ 35% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 09:03 UTC. This page is informational and not investment advice.